Notably, dual HDAC/BRAFV600E inhibitors based on the chemical structures of sorafenib and dabrafenib were meanwhile disclosed with higher antiproliferative activity against BRAFV600E-mutant cells (melanoma or CRC cells) compared with BRAF-wildtype cells[52,53]. Here, BRAF is linked to melanoma.